May 28, 2004American Journal of Clinical Oncology
Primary Mediastinal Large B-Cell Lymphoma
Key result
Doxorubicin-containing chemotherapy, followed by mediastinal radiotherapy in select cases, resulted in a median survival of 67.7 months among patients with primary mediastinal B-cell lymphoma.
Why the study?
What are the clinical features and treatment outcomes of doxorubicin-containing chemotherapy in patients with primary mediastinal B-cell lymphoma?
Population
20 patients with primary mediastinal B-cell lymphoma, median age 42 years, treated at centers participating…
Design
Cohort
Follow-up
median 91 months
Authors
Discussion
Loading...
Member takes
Overview
Supports doxorubicin regimens in PMBCL; extends single-center data but leaves open randomized comparisons.
Study Design
Type
Cohort (n=20)
Multicenter
Yes
Structured PICO
What are the clinical features and treatment outcomes of doxorubicin-containing chemotherapy in patients with primary mediastinal B-cell lymphoma?
P
Population
20 patients with primary mediastinal B-cell lymphoma (PMBCL), median age 42 years, treated at centers participating in the Hellenic Cooperative Oncology Group over the last 20 years.
I
Intervention
Doxorubicin-containing chemotherapy, followed in 11 cases by mediastinal radiotherapy.
O
Outcome
Median survivalhard clinical
In a Greek cohort of 20 patients with primary mediastinal B-cell lymphoma, treatment with doxorubicin-containing chemotherapy resulted in a median survival of 67.7 months, consistent with reports from other centers.
Cite This Study
Andreopoulou et al. (2004) conducted a cohort in Primary mediastinal B-cell lymphoma (n=20). Doxorubicin-containing chemotherapy with or without mediastinal radiotherapy was evaluated on Median survival (months). Doxorubicin-containing chemotherapy, followed by mediastinal radiotherapy in select cases, resulted in a median survival of 67.7 months among patients with primary mediastinal B-cell lymphoma.